SCHEMBL29975604

SCHEMBL29975604

O=C(O)c1c(F)ccc(Br)c1F

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 3/20 0.38
CES1 P23141 3/20 0.38
GPR17 Q13304 1/20 0.36
KDM4E B2RXH2 1/20 0.34
ASPH Q12797 1/20 0.34
KDM8 Q8N371 1/20 0.34
CAT P04040 1/20 0.34
CA1 P00915 2/20 0.33
CA2 P00918 2/20 0.33
CA12 O43570 1/20 0.33
CA7 P43166 1/20 0.33
CA9 Q16790 1/20 0.33
CA14 Q9ULX7 1/20 0.33
FABP4 P15090 1/20 0.33
LMNA P02545 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
ALB P02768 1/20 0.32
ANO1 Q5XXA6 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL671154 1.00 CES2 (0.38) CES2CES1GPR17KDM4EASPH
SCHEMBL6343820 0.83 CES2 (0.40) CES2CES1GPR17KDM4EASPH
SCHEMBL31258574 0.81 CES2 (0.47) CES2CES1KDM4EASPHKDM8
SCHEMBL365563 0.81 CES2 (0.47) CES2CES1KDM4EASPHKDM8
SCHEMBL30632655 0.81 DGAT1 (0.41) CES2CES1CA1CA2CA9
SCHEMBL30047468 0.81 KDM4E (0.41) CES2CES1GPR17KDM4EASPH
SCHEMBL21807887 0.81 CA1 (0.46) GPR17KDM4EASPHKDM8CA1
SCHEMBL28052874 0.81 ALDH1A1 (0.38) CES2CES1CA1CA2LMNA
SCHEMBL10325437 0.81 CES2 (0.37) CES2CES1LMNAMEN1KMT2A
SCHEMBL16555805 0.81 DGAT1 (0.41) CES2CES1CA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260115296-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES UNIV YALE (US) 2026-04-30 US disclosed
CN-117003670-B Preparation process of 4-bromo-2, 6-difluorobenzonitrile 杭州国瑞生物科技有限公司 2025-05-30 CN disclosed
CN-119176772-A Compound with Mrgpr X receptor inhibition effect and application thereof 博济医药科技股份有限公司 2024-12-24 CN disclosed
CN-117003670-A Preparation process of 4-bromo-2, 6-difluorobenzonitrile 杭州国瑞生物科技有限公司 2023-11-07 CN disclosed
CN-116802181-A Triazolopyridine compounds as kinase inhibitors 百时美施贵宝公司 2023-09-22 CN disclosed
CN-115697975-A Herbicidal cinnoline derivatives 先正达农作物保护股份公司 2023-02-03 CN disclosed
US-20230000994-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES YALE UNIVERSITY 2023-01-05 US disclosed
CN-115073282-A Method for rapidly preparing 3-bromo-2, 4-difluorobenzoic acid based on microchannel continuous flow technology 都创(重庆)医药科技有限公司 2022-09-20 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230000994-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES CRBN, ARAF, VHL CES2 3556/4885CES1 3150/4885GPR17 4465/4885
US-20260115296-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES CRBN, VHL, ADRM1 CES2 3298/4885CES1 2403/4885GPR17 4606/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.